NCT00004407终止不适用
Randomized Study of Intravenous Immunoglobulin (IVIg) in Patients With Subacute Proximal Diabetic Neuropathy
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- Mayo Clinic
- 入组人数
- 75
研究概览
简要总结
OBJECTIVES: I. Determine the effect of intravenous immunoglobulin on recovery time of patients with proximal diabetic neuropathy.
II. Determine whether rate of response is dose dependent in these patients.
详细描述
PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. Patients are randomized to treatment with low dose intravenous immunoglobulin (IVIg), high dose IVIg, or placebo.
Patients must first complete baseline evaluation. Patients receive IVIg or placebo on days 1, 2, 3, and 5, biweekly at weeks 2-4, weekly at weeks 5-8, and every other week at weeks 9-12.
Patients are assessed at 6, 12, 36, 52, and 104 weeks.
Completion date provided represents the completion date of the grant per OOPD records
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •PROTOCOL ENTRY CRITERIA:
- •-Disease Characteristics--
- •Diagnostically proven non-insulin dependent diabetes mellitus as defined by the following criteria: Presence of classic symptoms, such as polyuria, polydipsia, ketonuria, and rapid weight loss, together with plasma glucose elevations Elevated fasting glucose concentration on more than one occasion
- •Diagnostically proven proximal diabetic neuropathy with any of the following symptoms: Severe thigh, hip, or leg pain Greater than 20% weight loss Progressive proximal weakness in the painful leg Weakness in the contralateral lower limb Thoracic or cervical root distribution Symmetric distal polyneuropathy or autonomic neuropathy may be mild or absent
- •-Prior/Concurrent Therapy--
- •At least 6 months since prior immunosuppression or plasma exchange
- •No history of prior renal transplant
- •-Patient Characteristics--
- •Age: 18 and over
- •Performance status: Gait impairment at least grade 2
- •Hematopoietic: Not specified
- •Hepatic: Not specified
- •Renal: Creatinine no greater than 1.4 mg/dL (women) Creatinine no greater than 1.5 mg/dL (men) No history of renal failure
- •Cardiovascular: No history of cardiac failure
- •Neurologic: Normal nerve conduction studies or changes compatible with distal symmetric diabetic neuropathy or diabetic lumbosacral radioplexus neuropathy Spinal fluid cell count less than 5 cells/mm3 Normal cerebral spinal fluid cytology No structural spine disease No inherited neuropathy
- •Other: Electromyographic evidence of proximal lower limb plexus OR Radicular denervation compatible with proximal diabetic neuropathy No other systemic disease or malignancy Normal IgA levels No chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No systemic amyloidosis No monoclonal gammopathy associated neuropathy No history of allergy to serum products No selective cervical or root involvement without lower limb weakness No evidence of secondary diabetes
排除标准
- 未提供
研究者
相似试验
终止
不适用
Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia GravisMyasthenia GravisNCT00004682University of Texas100
撤回
3 期
Intravenous Immunoglobulins in Complex-regional Pain SyndromeComplex Regional Pain Syndrome Type 1NCT00949065University of Giessen
终止
3 期
Intravenous Immunoglobulin After Relapse in VasculitisANCA + Vasculitides Relapsing Either Under Corticosteroidand Immunosuppressant Therapies or After One YearPost Treatment.NCT00307658Assistance Publique - Hôpitaux de Paris40
招募中
4 期
Efficacy of Intravenous Immunoglobulin in Patients With Hemorrhagic Fever With Renal Syndrome: a Prospective StudyHFRS (Hemorrhagic Fever With Renal Syndrome)NCT06009042Tongji Hospital100
终止
4 期
A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated MyelopathyHIV-associated MyelopathyNCT01561755David M. Simpson12